PrimeRFP SCOUT · Federal Contract Recompete Brief

W81K0024D0004Modified quantities for SLINS 1001aa and — Novartis Pharmaceuticals Corp

Novartis Pharmaceuticals Corp holds $23.5M across 59 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 5 related awards in the incumbent pipeline. Set-aside status: NONE.

W40m Mrc0 West
Awarding office
Novartis Pharmaceuticals Corp
Recipient
Estimated value
6505
PSC
NONE
Set-aside

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Novartis Pharmaceuticals Corp — $90

Contract facts

NONE
Contract numberW81K0024D0004
Also listed asW81K00-24-D-0004
AgencyW40m Mrc0 West
Awarding officeW40m Mrc0 West
Awarding agencyDepartment of Defense (DOD)
Funding agencyDepartment of Defense (DOD)
IncumbentNovartis Pharmaceuticals Corp
UEING61ZA8TADW3
PSC6505
Related solicitationW81K0024R0020

MODIFIED QUANTITIES FOR SLINS 1001AA AND 1001AB FOR ORDERING PERIOD FROM 1 OCT 25 TO 31 DEC 25 WHEREAS SLINS 1001AC AND 1001AD HAD UPDATED UNIT PRICING AND CHANGE IN QUANTITIES FOR ORDERING PERIOD FROM 1 JAN 26 TO 30 SEPT 26. is a federal NONE award for W40m Mrc0 West held by Novartis Pharmaceuticals Corp. Estimated value —. Related solicitation W81K0024R0020.

MODIFIED QUANTITIES FOR SLINS 1001AA AND 1001AB FOR ORDERING PERIOD FROM 1 OCT 25 TO 31 DEC 25 WHEREAS SLINS 1001AC AND 1001AD HAD UPDATED UNIT PRICING AND CHANGE IN QUANTITIES FOR ORDERING PERIOD FROM 1 JAN 26 TO 30 SEPT 26.

Incumbent footprint

Public record

Novartis Pharmaceuticals Corp$23.5M obligated across 59 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).

% of firm-wide obligated ($23.5M) · all agencies
Department of Veterans Affairs (VA)$37.6M · 160%Department of Defense (DOD)$4.7M · 20%
Open full company profile

Related awards

Same incumbent
36C24826F0082
PLUVICTO
$4.7M
Aug 31, 2026
36C25025F0726
PLUVICTO RADIOPHARMACEUTICAL - CLEVELAND VAMC
$400K
Aug 31, 2026
36C24125F0148
PLUVICTO
$810K
Sep 14, 2026
36C26126F0007
PLUVICTO DRUG
$4.0M
Sep 30, 2026
W81K0025FA195
LUTATHERA AND PLUVICTO
$3.2M
Sep 30, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract W81K0024D0004?

W81K0024D0004 (Modified quantities for SLINS 1001aa and) is a W40m Mrc0 West award with an estimated value of —, currently held by Novartis Pharmaceuticals Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is W81K00-24-D-0004?

W81K00-24-D-0004 is the dashed form of PIID W81K0024D0004 (Modified quantities for SLINS 1001aa and), held by Novartis Pharmaceuticals Corp. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded W81K0024D0004?

W40m Mrc0 West awarded W81K0024D0004 to Novartis Pharmaceuticals Corp.

Who is the incumbent on W81K0024D0004?

Novartis Pharmaceuticals Corp is the incumbent with $23.5M across 59 related awards in SCOUT’s public footprint.

When does Novartis Pharmaceuticals Corp’s W81K0024D0004 come up for recompete?

SCOUT tracks a period-of-performance end of an unstated date. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthly
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/W81K0024D0004